
Photo by Jeremy Bishop on Unsplash
Inova Schar Cancer is one of the top recruiting locations for the EMBER-4 clinical trial, a global study to evaluate a new treatment for ER+ HER2- breast cancer survivors
EMBER-4 is a Phase 3 clinical trial comparing a new drug therapy, imlunestrant, to the standard drug therapy to treat women with ER+ HER2- breast cancer. The trial is being conducted at multiple locations around the world, with Inova Schar Cancer named as one of the top recruiting centers in the United States.
“This pill is the first therapy in 30 years that could potentially replace endocrine therapy,” said study Kathleen Harnden, MD, Medical Director of Breast Oncology at Inova Schar Cancer and the principal investigator for the EMBER-4 clinical trial at Inova Schar Cancer. “This study is a bit of a unicorn. It is extremely patient centered and provides a rare opportunity to evaluate a treatment that may be better, with a higher cure rate, a lower risk of spread of breast cancer and fewer side effects.”
(more…)